Share

February 2018; 8 (1) Review

Lower prevalence of multiple sclerosis in First Nations Canadians

Ruth Ann Marrie, Stella Leung, Nancy Yu, Lawrence Elliott
First published January 23, 2018, DOI: https://doi.org/10.1212/CPJ.0000000000000418
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
32

Share

Article Information

vol. 8 no. 1 33-39
DOI: 
https://doi.org/10.1212/CPJ.0000000000000418
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received July 12, 2017
  • Accepted August 18, 2017
  • First Published January 23, 2018.

Article Versions

Copyright & Usage: 
© 2018 American Academy of Neurology

Author Disclosures

    1. Ruth Ann Marrie, MD, PhD,
    2. Stella Leung, MSc,
    3. Nancy Yu, PhD and
    4. Lawrence Elliott, MD, MSc
  1. Ruth Ann Marrie, MD, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neurology, Editorial Board Multiple Sclerosis Journal, Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Received support as site Principal Investigator for clinical trials from Sanofi- Aventis (2007-2015)

    Research Support, Government Entities:

    1. Received support as principal investigator from the Canadian Institutes of Health Research (2010-2019), and Research Manitoba (2014-2019).

    Research Support, Academic Entities:

    1. Waugh Family Chair in Multiple Sclerosis

    Research Support, Foundations and Societies:

    1. Received support as principal investigator from Multiple Sclerosis Society of Canada (2009-2016) and the National Multiple Sclerosis Society (2013-2017), and as co-principal investigator from Multiple Sclerosis Scientific Foundation (2009-2018). Received support from Consortium of Multiple Sclerosis Centers (2004-2009, 2011-2014, 2016-2017), Rx & D Health Research Foundation (2010-2015), Crohn's and Colitis Canada (2014- 2019)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Stella Leung, MSc,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Nancy Yu, PhD and
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) Building capacity to respond to HIV/AIDS in China/CIDA, co-investigator, 01/04/2007 to 31/03/2013. (2) Burden of diabetes in Manitoba/PHAC (via Manitoba Health & Healthy Living), Principal Investigor, 01/04/09 to 31/03/2010. (3)The development of a surveillance tool for Chronic Kidney Disease and End Stage Renal Disease in Manitoba/PHAC, co-applicant, 01/07/2009 to 31/07/2011.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. CIHR ($2,498,495, 2013/4 - 2018/3), Advancing primary healthcare for persons living with HIV in Canada, co- investigator, PI Dr. Clare Liddy. Multiple Sclerosis Society of Canada ($155,599, 2012/7 - 2015/6), The impact of comorbidity and secular time on hospitalizations and mortality in MS, co-investigator, PI Dr. Ruth Ann Marrie. National Multiple Sclerosis Society ($317,843, 2012/7- 2015/6), Adherence to immunomodulators in Multiple Sclerosis: prevalence and clinical impact (the AIMS Study), collaborator, PI Dr. Helen Tremlett. CIHR Emerging Team Grant ($1,500,000, 2010/4 - 2015/3), Team in the epidemiology & impact of comorbidity on MS (ECoMS), co-investigator, PI Dr. Ruth Ann Marie. Gilead Sciences ($96,000, 2013/4 - 2014/3). Missed opportunities for diagnosis for HIV epidemiological study (MODES Manitoba), co-investigator, PI Dr. Marissa Becker. CIDA(International development grant, $20,000), Building capacity to respond to HIV/AIDS in China: Extending the impact. Co-investigator, PI Dr. James Blanchard. CIHR Emerging Team: HIV/AIDS vaccine discovery and social research ($750,000), Team in the socio-cultural aspects of implementing HIV vaccine programs among MSM and FSWs in Asia and Africa. co-investigator, PI Dr. Robert Lorway. CIDA (International development grant, $990,000), Capacity building to respond to HIV/AIDS in China. Co- investigator, PI Dr. James Blanchard.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Lawrence Elliott, MD, MSc
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Departments of Internal Medicine (RAM), Community Health Sciences (RAM, SL, NY, LE), and Medical Microbiology (LE), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
  1. Correspondence
    Dr. Marrie rmarrie{at}hsc.mb.ca

Article usage

Article usage: January 2018 to October 2023

AbstractFullPdfSource
Jan 20187804Highwire
Feb 2018323216Highwire
Mar 2018492107Highwire
Apr 201829142Highwire
May 20188200Highwire
Jun 20187500Highwire
Jul 20185900Highwire
Aug 20185600Highwire
Sep 20185001Highwire
Oct 20184202Highwire
Nov 20185600Highwire
Dec 20187210Highwire
Jan 20196600Highwire
Feb 20196010Highwire
Mar 20195800Highwire
Apr 20193500Highwire
May 20193500Highwire
Jun 20191910Highwire
Jul 20192200Highwire
Aug 20192900Highwire
Sep 20191400Highwire
Oct 20191602Highwire
Nov 20191100Highwire
Dec 2019800Highwire
Jan 20201300Highwire
Feb 20202400Highwire
Mar 20201300Highwire
Apr 2020911Highwire
May 2020700Highwire
Jun 2020700Highwire
Jul 2020600Highwire
Aug 20201100Highwire
Sep 2020900Highwire
Oct 20201200Highwire
Nov 20201300Highwire
Dec 20201700Highwire
Jan 20213200Highwire
Feb 20212011Highwire
Mar 20212300Highwire
Apr 20211000Highwire
May 20211600Highwire
Jun 20212100Highwire
Jul 20211500Highwire
Aug 20213600Highwire
Sep 20211300Highwire
Oct 20213000Highwire
Nov 20211600Highwire
Dec 20212800Highwire
Jan 20222100Highwire
Feb 20221800Highwire
Mar 20222700Highwire
Apr 20222200Highwire
May 20222610Highwire
Jun 20221711Highwire
Jul 20223933Highwire
Aug 20221310Highwire
Sep 20222320Highwire
Oct 20222120Highwire
Nov 20225440Highwire
Dec 20222110Highwire
Jan 20232230Highwire
Feb 20232221Highwire
Mar 20231611Highwire
Apr 20231400Highwire
May 20231600Highwire
Jun 2023800Highwire
Jul 20232410Highwire
Aug 20231900Highwire
Sep 20231300Highwire
Oct 2023700Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles